Skip to main content
Equibles
ADCT logo

ADCT · ADC Therapeutics SA · Metrics

Track ADCT — free

Use ADCT with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ADCT.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$1.59 +0.00 (+0.00%) Q1 2026 earnings call transcript
Russell 2000 member Rebalance outlook locked
Market Cap
$202.99M
Shares
127.67M
Volume · Oct 27 1.25M Avg daily vol (3M) 1.55M

ADCT metrics

70 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$1.59
Market cap
$202.99M

Price action

20 metrics
Price change (1W)
+4.6%
Price change (30D)
+26.2%
Price change (3M)
+43.2%
Price change (6M)
-57.8%
Price change (YTD)
-55.0%
Price change (1Y)
-62.9%
Trailing year
Price change (5Y)
-94.3%
52-week high
$4.88
52-week low
$0.96
Change from 52-week high
-67.4%
Change from 52-week low
+65.6%
Annualized volatility
97.9%
Annualized volatility (3M)
96.2%
Beta
1.3
RSI (14D)
57.4
Price vs SMA 50
+24.8%
Price vs SMA 200
-36.7%
Avg volume (3M)
1.55M
Relative volume
0.8
Average dollar volume
$1.94M

Company

3 metrics
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Shares outstanding
127.67M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
2.6×
reciprocal yield 39.2%
P / book
—
FCF yield
-50.4%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-47.7%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-13

Profitability

9 metrics
Gross margin
92.9%
Operating margin
-125.1%
Trailing 12 months
Net margin
-121.8%
Gross profit (TTM)
$67.03M
Operating profit (TTM)
−$99.55M
Net income (TTM)
−$96.91M
Trailing 12 months
Diluted EPS (TTM)
$-0.58
FCF margin
-128.5%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
$0.82
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$-1.48

Growth

11 metrics
Revenue growth YoY
+2.2%
Year over year
Net income growth YoY
—
Revenue (TTM)
$79.58M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+36.3%
Year over year · more shares
Revenue CAGR (3Y)
-27.1%
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
—
Return on assets
-34.7%
Debt / equity
—
Current ratio
3.0
EBITDA (TTM)
−$135.38M
Free cash flow (TTM)
−$102.30M
Quick ratio
3.0
Interest coverage
-1.9
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$219.11M
Total assets
$279.38M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$102.27M
Capital expenditures (TTM)
$32,000
R&D (TTM)
$82.23M
SG&A (TTM)
—
Stock compensation (TTM)
$9.66M
R&D / revenue
103.3%
Stock compensation / revenue
12.1%

Ownership (13F)

9 metrics
13F filers
113
13F filer change QoQ
-5
Institutional ownership
63.4%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
35.4%
Private-fund adviser ownership
28.4%
Active holders' share change QoQ
-5.1%
Holder tenure
11.2
Price vs estimated holder cost
-81.4%

Ownership (registered funds)

1 metrics
Index-fund ownership
0.7%

Short interest

3 metrics
Short interest
5.0%
Latest settlement · 2.9 days to cover
Days to cover
2.9d
Short-squeeze score
55 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1771910 CUSIP H0036K147 13F (30d) 18 filings 18 filers Visit website Investor relations